ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings

MT Newswires Live03-20

ARS Pharmaceuticals (SPRY) reported Q4 net income Thursday of $0.48 per diluted share.

Three analysts surveyed by FactSet expected a loss of $0.04.

Revenue for the quarter ended Dec. 31 was $86.6 million.

For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.

Four analysts polled by FactSet expected a loss of $0.52.

Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.

As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.

Shares of the company were up more than 7% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2520458570?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-20 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520458570","market":"fut","top_or_hot":-1,"title":"ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings","media":"MT Newswires Live","content":"<html><body><p> ARS Pharmaceuticals (SPRY) reported Q4 net income Thursday of $0.48 per diluted share.</p><p>Three analysts surveyed by FactSet expected a loss of $0.04.</p><p>Revenue for the quarter ended Dec. 31 was $86.6 million.</p><p>For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.</p><p>Four analysts polled by FactSet expected a loss of $0.52.</p><p>Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.</p><p>As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.</p><p>Shares of the company were up more than 7% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-20 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ARS Pharmaceuticals (SPRY) reported Q4 net income Thursday of $0.48 per diluted share.</p><p>Three analysts surveyed by FactSet expected a loss of $0.04.</p><p>Revenue for the quarter ended Dec. 31 was $86.6 million.</p><p>For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.</p><p>Four analysts polled by FactSet expected a loss of $0.52.</p><p>Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.</p><p>As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.</p><p>Shares of the company were up more than 7% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2520458570","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520458570","pubTimestamp":1742470475,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ARS Pharmaceuticals  reported Q4 net income Thursday of $0.48 per diluted share.Three analysts surveyed by FactSet expected a loss of $0.04.Revenue for the quarter ended Dec. 31 was $86.6 million.For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.Four analysts polled by FactSet expected a loss of $0.52.Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.Shares of the company were up more than 7% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"ARS Pharmaceuticals报告第四季度业绩，2024年盈利波动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRY":0.9},"content_text":"ARS Pharmaceuticals (SPRY) reported Q4 net income Thursday of $0.48 per diluted share.Three analysts surveyed by FactSet expected a loss of $0.04.Revenue for the quarter ended Dec. 31 was $86.6 million.For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.Four analysts polled by FactSet expected a loss of $0.52.Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.Shares of the company were up more than 7% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2520458570"}